Symptom identification and management in epithelial ovarian cancer.

Authors

null

Ashley Hickman

Mayo Clinic Department of Internal Medicine, Rochester, MN

Ashley Hickman , Kathryn Jean Ruddy , Deirdre R. Pachman , Kristin Fischer , Parvez Rahman , Krista M. Goergen , Minji Lee , Andrea L. Cheville , Andrea Elisabeth Wahner Hendrickson

Organizations

Mayo Clinic Department of Internal Medicine, Rochester, MN, Department of Medical Oncology, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN, Mayo Clinic Rochester, Rochester, MN

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health

Background: A better understanding regarding the burden of treatment side effects in patients with gynecological malignancies could help guide symptom interventions and oncologic therapy decision-making. We aim to inform understanding of symptom burden in epithelial ovarian cancer (EOC) by analyzing patient-reported symptom data from patients treated for this condition over a 16-month period. Methods: Patients receiving medical oncology care at Mayo Clinic Rochester and at Midwest Mayo Clinic Health System community sites have received symptom-focused surveys prior to each medical oncology visit since March 28, 2019 through the Enhanced Electronic Health Record Facilitated Cancer Symptom Control Study (E2C2). These surveys, administered either through the electronic medical record portal or on a clinic tablet prior to each oncology office visit, no more frequently than every 2 weeks, include six linear analogue scales measuring sleep disturbance, pain, anxiety, emotional distress, and fatigue (SPADE), as well as physical dysfunction on a scale of 0 (none) to 10 (as bad as you can imagine). Scores of 0-3 were considered mild symptoms, 4-6 moderate symptoms, and 7-10 severe symptoms. We collected survey results from March 28, 2019 to July 20, 2020 for patients with EOC and reviewed the number of surveys per patient in addition to the average symptom scores. Results: From March 2019 to July 2020, for patients with EOC, there were 2974 encounter-based surveys from 762 patients. The number of surveys completed by each patient ranged from 1-20. The following number of patients returned the correlating number of surveys: 1 survey:240 patients; 2 surveys:145; 3 surveys:79; 4 surveys:56; 5 surveys:58; 6 surveys:45; 7 surveys:38; 8 surveys:27; 9 surveys:22; ≥10 surveys:52. The average score from all surveys for each symptom was: 2.41 for sleep disturbance, 2.03 for pain, 2.32 for anxiety, 1.97 for emotional distress, 3.26 for fatigue, and 2.50 for physical dysfunction. Please see the table for the proportion of surveys that reported symptoms as mild, moderate, or severe. Conclusions: Fatigue and physical dysfunction were reported most frequently in patients with EOC, while emotional distress and pain were reported least frequently. 20% of surveys reported moderate to severe emotional distress, while 40% reported moderate to severe fatigue. A targeted approach to symptom management is needed for patients undergoing EOC evaluation and treatment. Our next steps in this analysis include an assessment of potential predictors of greater symptom burden (e.g., specific treatments, age, and other clinical and sociodemographic characteristics). Clinical trial information: NCT03892967


Sleep Disturbance
Pain
Anxiety
Emotional Distress
Fatigue
Physical Dysfunction
Mild (0-3)
71.8%
77.9%
74.9%
79.6%
60.0%
69.4%
Moderate (4-6)
20.5%
16.3%
18.7%
15.5%
27.8%
22.7%
Severe (7-10)
7.7%
5.8%
6.4%
4.9%
12.2%
7.9%

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03892967

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5554)

DOI

10.1200/JCO.2021.39.15_suppl.5554

Abstract #

5554

Poster Bd #

Online Only

Abstract Disclosures

Similar Abstracts

First Author: Michael H. Storandt

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Symptom burden and functioning status in patients with advanced upper gastrointestinal cancers.

First Author: Xin Shelley Wang